Sign In
Buy NRXP
$4.05
-0.570 (-12.34%)
At Close: Jun 03, 2026
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update
08:10am, Monday, 18'th Aug 2025
NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet medi
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025
06:06pm, Wednesday, 13'th Aug 2025
Conference Call 8:00am ET, Wednesday August 20, 2025 WILMINGTON, Del. , Aug. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025
04:05pm, Monday, 11'th Aug 2025
WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it
This designation expands the addressable population for NRX-100 to the 13 million Americans who consider suicide each year and represents a 10x expansion of the addressable population compared to the
Florida's Agency for Health Care Administration (AHCA) approval is a critical regulatory step toward closing the Dura Medical acquisition Dura Medical, together with previously-announced acquisitions
Sterile ketamine products currently for sale in the United States contain benzethonium chloride, a preservative with known toxicity that is not Generally Recognized as Safe and Effective by the US Foo
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join Fireside Chat at BTIG Virtual Biotech Conference July 29 - 30, 2025
08:03am, Tuesday, 29'th Jul 2025
WILMINGTON, Del. , July 29, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), today announced that its CEO and Chairman will join a fireside chat
Cohen and Associates is a highly respected neuropsychiatry clinic in western Florida Cohen to serve as foundational clinic in the Sarasota - Bradenton area of Florida Acquisition expected to be immedi
Company has applied for new Commissioner's National Priority Vouchers (CNPV) for NRX-100. Continues to anticipate decisions on drug approval by year-end 2025 Application under CNPV program is accretiv
WILMINGTON, Del. , June 16, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeu
WILMINGTON, Del. , June 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeu
Squarepoint Ops LLC Makes New Investment in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)
03:34am, Wednesday, 11'th Jun 2025
Squarepoint Ops LLC purchased a new position in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP – Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchang
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine
08:03am, Thursday, 05'th Jun 2025
Ketamine faces a current US drug shortage not expected to abate in the near future1 Current ketamine market estimated at $750 million and projected to reach $3.35 billion globally in 2034.2 NRx ant
NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript
08:46pm, Friday, 16'th May 2025
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Matthew Duffy – Chief Business Officer Jonathan Javitt – Founder, Chairman, a
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update
04:03pm, Thursday, 15'th May 2025
Company has continued to advance its previously announced plan to obtain FDA approval for two new drugs and to develop a network of clinics focused on neuroplastic therapies to treat severe and suicid
